Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 605

1.

Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Wares M, Hassounah S, Mesplède T, Sandstrom PA, Wainberg MA.

Antimicrob Agents Chemother. 2015 Jan 12. pii: AAC.04829-14. [Epub ahead of print]

PMID:
25583721
[PubMed - as supplied by publisher]
2.

Differential effects of the G118R, H51Y and E138K resistance substitutions in HIV integrase of different subtypes.

Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA.

J Virol. 2014 Dec 31. pii: JVI.03353-14. [Epub ahead of print]

PMID:
25552724
[PubMed - as supplied by publisher]
3.

How will the ebola crisis impact the HIV epidemic?

Wainberg MA, Lever AM.

Retrovirology. 2014 Nov 30;11(1):110. [Epub ahead of print]

PMID:
25472763
[PubMed - as supplied by publisher]
Free PMC Article
4.

HIV and Ebola: similarities and differences.

Wainberg MA, Kippax S, Bras M, Sow PS.

J Int AIDS Soc. 2014 Dec 1;17:19896. doi: 10.7448/IAS.17.1.19896. eCollection 2014. No abstract available.

PMID:
25466882
[PubMed - in process]
Free PMC Article
5.

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2014 Nov 27. pii: dku451. [Epub ahead of print]

PMID:
25433008
[PubMed - as supplied by publisher]
6.

The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir.

Cutillas V, Mesplede T, Anstett K, Hassounah S, Wainberg MA.

Antimicrob Agents Chemother. 2015 Jan;59(1):310-6. doi: 10.1128/AAC.04274-14. Epub 2014 Oct 27.

PMID:
25348535
[PubMed - in process]
7.

Trichiconins A-C, limonoids with new carbon skeletons from Trichilia connaroides.

Liu CP, Xu JB, Han YS, Wainberg MA, Yue JM.

Org Lett. 2014 Oct 17;16(20):5478-81. doi: 10.1021/ol5027552. Epub 2014 Oct 8.

PMID:
25296007
[PubMed - in process]
8.

A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load.

Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C.

PLoS One. 2014 Oct 8;9(10):e109420. doi: 10.1371/journal.pone.0109420. eCollection 2014.

PMID:
25295725
[PubMed - in process]
Free PMC Article
9.

Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines.

Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA.

Virol J. 2014 Oct 6;11:177. doi: 10.1186/1743-422X-11-177.

PMID:
25287969
[PubMed - in process]
Free PMC Article
10.

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.

Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M.

J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.

PMID:
25281399
[PubMed - in process]
11.

Eurifoloids A-R, structurally diverse diterpenoids from Euphorbia neriifolia.

Zhao JX, Liu CP, Qi WY, Han ML, Han YS, Wainberg MA, Yue JM.

J Nat Prod. 2014 Oct 24;77(10):2224-33. doi: 10.1021/np5004752. Epub 2014 Sep 25.

PMID:
25252924
[PubMed - indexed for MEDLINE]
12.

Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency.

Bastarache SM, Mesplède T, Donahue DA, Sloan RD, Wainberg MA.

Viruses. 2014 Sep 19;6(9):3487-99. doi: 10.3390/v6093487.

PMID:
25243372
[PubMed - in process]
Free PMC Article
13.

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.

Depatureaux A, Quashie PK, Mesplède T, Han Y, Koubi H, Plantier JC, Oliveira M, Moisi D, Brenner B, Wainberg MA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7141-50. doi: 10.1128/AAC.03819-14. Epub 2014 Sep 15.

PMID:
25224008
[PubMed - in process]
14.

Early immune adaptation in HIV-1 revealed by population-level approaches.

Martin E, Carlson JM, Le AQ, Chopera DR, McGovern R, Rahman MA, Ng C, Jessen H, Kelleher AD, Markowitz M, Allen TM, Milloy MJ, Carrington M, Wainberg MA, Brumme ZL.

Retrovirology. 2014 Aug 29;11(1):64. doi: 10.1186/s12977-014-0064-1.

PMID:
25212686
[PubMed - in process]
Free PMC Article
15.

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

Mesplède T, Wainberg MA.

Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.

PMID:
25166745
[PubMed - in process]
Free PMC Article
16.

Integrase Strand Transfer Inhibitors in HIV Therapy.

Mesplède T, Wainberg MA.

Infect Dis Ther. 2013 Dec;2(2):83-93. doi: 10.1007/s40121-013-0020-8. Epub 2013 Nov 19.

PMID:
25134473
[PubMed]
Free PMC Article
17.

The 20th International AIDS Conference: where do we go from here?

Wainberg MA, Kippax S, Bras M, Salif Sow P.

J Int AIDS Soc. 2014 Jul 18;17:19331. doi: 10.7448/IAS.17.1.19331. eCollection 2014. No abstract available.

PMID:
25043381
[PubMed - in process]
Free PMC Article
18.

Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.

Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N.

J Int AIDS Soc. 2014 Jul 4;17:18944. doi: 10.7448/IAS.17.1.18944. eCollection 2014. Review.

PMID:
24998532
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

PMID:
24920794
[PubMed - indexed for MEDLINE]
20.

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA.

J Antimicrob Chemother. 2014 Oct;69(10):2733-40. doi: 10.1093/jac/dku199. Epub 2014 Jun 10.

PMID:
24917583
[PubMed - in process]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk